Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-579-3p
- Development stage
- Preclinical
- Lead developer
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
miR-579-3p is a tumor-suppressive microRNA that acts as a master regulator of melanoma progression and drug resistance. It functions by post-transcriptionally downregulating the expression of key oncoproteins, specifically BRAF and MDM2. Research indicates that miR-579-3p levels are high in nevi but significantly decline in stage III-IV melanomas and further decrease in cells that have developed resistance to BRAF and MEK inhibitors. Therapeutic restoration or overexpression of miR-579-3p has been shown to inhibit melanoma cell growth and migration, induce apoptosis, and impair the establishment of resistance to targeted therapies. It is being investigated as a potential therapeutic intervention for BRAF-mutated metastatic melanoma.
- Other names
- microRNA-579-3pmicroRNA579-3pmicroRNA 579-3phsa-miR-579-3phsa-miR579-3phsa-miR 579-3p
02
Targets
MDM2 (Mouse double minute 2 homolog)BRAF (B-Raf proto-oncogene, serine/threonine kinase)
Beyond the preview
Go deeper on miR-579-3p.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-579-3p.